Kisspeptin for fertility: reading the trials past the marketing

Kisspeptin shows up in nearly every peptide-vendor fertility pitch right now, usually next to a line about "restoring your fertility hormones" or "resetting your cycle." Short answer: kisspeptin for fertility rests on a genuinely important mechanism, and the human data behind it is real, but most of the trials that get cited measure sexual desire and hormone activation. None of them track pregnancy directly. I've read through the actual studies more than once because clients keep asking me the same question, and the gap between what gets sold and what got measured is worth walking through.

The mechanism that earns kisspeptin its reputation

Kisspeptin is a neuropeptide made in the hypothalamus, and it sits one step above everything else in the chain that runs your reproductive hormones. Kisspeptin binds a receptor called KISS1R on the neurons that release GnRH, GnRH tells the pituitary to release LH and FSH, and LH and FSH tell the ovaries or testes to do their job. The reason kisspeptin gets called the master switch is a 2003 finding: people born with a non-working KISS1R gene never go through puberty at all, and a second research group found the same thing independently that same year. Without a working kisspeptin signal, the whole cascade never turns on in the first place. That is a real, structural argument for why kisspeptin matters to fertility, and it is where most of the marketing stops digging. The Kisspeptin-10 encyclopedia page covers the full mechanism map if you want the deeper version.

What the human dosing trials actually measured

Here is where I want you to slow down. When a vendor cites "clinical trials" for kisspeptin, they are almost always pointing at the same small cluster of studies out of Imperial College London, and those studies were sexual-desire trials. In 32 men with low sexual desire, a kisspeptin infusion increased activity in sexual-processing brain regions and boosted physical arousal measures compared to placebo. The companion trial ran the same protocol in 32 premenopausal women with low desire, and it turned up something genuinely useful for the mechanism question: kisspeptin raised LH and FSH exactly as predicted, but estradiol, progesterone, and testosterone did not move. That tells you kisspeptin's effect on desire runs through a direct brain pathway, separate from downstream sex hormone changes. That is useful science about the mechanism, but it does not establish a fertility outcome.

A separate review pooling the dosing studies found that a single kisspeptin dose raises LH by roughly two to three times baseline in most people, confirming the axis responds the way the mechanism predicts. What none of these studies report is a pregnancy rate, an ovulation rate, or a live birth. The studies confirm kisspeptin flips the switch. Getting someone pregnant is a separate question the data hasn't answered yet.

Where that leaves someone actually trying to conceive

So where does this leave a woman charting cycles or a man looking at a low LH and FSH panel. If bloodwork shows LH and FSH sitting low along with low estrogen or testosterone, that pattern points at the top of the cascade, and kisspeptin is aimed at exactly that failure point. If LH and FSH are already high while estrogen or testosterone stays low, the problem sits in the ovaries or testes themselves, and kisspeptin has no mechanism for fixing a problem at that level. I see people skip that distinction constantly, and it is the single most important thing to check before spending money on a vial for this specific use.

What the evidence supports right now is HPG-axis activation, a confirmed LH and FSH response, and a direct brain effect on desire that does not depend on hormone levels changing. What it does not yet include is a published trial tracking cycle regularity, confirmed ovulation, or pregnancy in people using kisspeptin specifically to conceive. The mechanism is about as solid as mechanism evidence gets in this field, but the marketing is running ahead of the outcome data, and anyone using kisspeptin for fertility right now is extrapolating from a mechanism trial, the same way a lot of the peptide world extrapolates from animal data to human dosing every day. If you are also weighing whether to add a second compound on top of it, the piece on stacking kisspeptin with oxytocin walks through when a second peptide actually earns its place versus when it is just adding cost.

Mood, safety, and the practical dosing picture

On safety, the data is reassuring. A 2025 trial specifically tested whether ramping up this axis triggers anxiety, since some people worry that any hormone-cascade activator will make them wired, and it found kisspeptin does not move anxiety in either direction. An earlier brain-imaging study had already found kisspeptin turned down activity tied to negative mood while it turned up activity in reward and bonding regions during sexual and emotional stimuli. Across the published trials, side effects have been minor: mild injection-site irritation, occasional flushing, and headache in a small number of users.

On the ground, people running Kisspeptin-10 for HPG-axis support typically dose in the range of 100 to 300 mcg, injected more than twice a week and often daily, because the short half-life means a once-a-week dose does not create the pulsing pattern the receptor actually needs. Cycles for axis-restoration purposes usually run 4 to 12 weeks with bloodwork rechecked at the end. Reconstituting a 5 mg vial with 2.5 mL of bacteriostatic water gives you 2,000 mcg per mL, so a 200 mcg dose lands at 10 units on a standard insulin syringe.

Now the part my lawyer makes me say, and he is right about it: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

For a physician-prescribed route, see OHM's telehealth page; for research-use-only sourcing and OHM's vendor disclosures, see Where to buy.

Anyone chasing kisspeptin specifically for a fertility outcome needs to treat it as what the trials actually show: a compound that reliably activates the top of the reproductive cascade, with real mechanism support behind it, and not yet a proven fertility treatment in its own right. If your workup points to a genuine upstream hormone problem, that is worth a real conversation with a provider who can check labs before and after.